XML 67 R53.htm IDEA: XBRL DOCUMENT v3.20.2
License agreements - Agenus (Details)
$ / shares in Units, $ in Thousands, shares in Millions
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Feb. 14, 2017
USD ($)
$ / shares
Feb. 01, 2017
USD ($)
$ / shares
shares
Dec. 31, 2017
USD ($)
Feb. 28, 2017
USD ($)
Nov. 30, 2015
item
Jan. 31, 2015
USD ($)
item
Sep. 30, 2020
USD ($)
$ / shares
shares
Jun. 30, 2020
USD ($)
$ / shares
shares
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
$ / shares
Sep. 30, 2019
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
License agreements                            
Long term investments             $ 222,810     $ 222,810     $ 133,657  
Research and development expense             438,109   $ 281,336 1,809,997 $ 841,244      
Unrealized gain (loss) on long term investments             (13,207)   2,339 10,935 18,703      
Total revenues             620,643   551,581 1,877,193 1,579,370      
Net income                   (445,547) 335,901      
Current assets             2,159,425     2,159,425     2,481,488  
Current liabilities             606,202     $ 606,202     513,340  
Minimum                            
License agreements                            
Royalty payments on future global net sales (as a percent)     15.00%                      
Agenus                            
License agreements                            
Number of program targets | item         3 4                
Royalty payments on future global net sales (as a percent)                   15.00%        
Upfront payment under license agreement           $ 60,000                
Period of notice for termination of license agreement       12 months                    
Agenus | Development, Regulatory and Commercialization Milestones | Minimum                            
License agreements                            
Royalty payments on future global net sales (as a percent)                   6.00%        
Agenus | Development, Regulatory and Commercialization Milestones | Maximum                            
License agreements                            
Royalty payments on future global net sales (as a percent)                   12.00%        
Additional milestone payments under the license agreement       $ 510,000                    
Agenus | Development Milestones                            
License agreements                            
Upfront payment under license agreement                       $ 20,000    
Additional milestone payments under the license agreement                           $ 5,000
Agenus                            
License agreements                            
Long term investments             56,200     $ 56,200     72,300  
Research and development expense             $ 100   400 $ 400 1,300      
Shares divested (in shares) | shares             2.5 1.2            
Ownership percentage (as a percent) 18.00%           7.70% 9.80%   7.70%        
Gross proceeds from sale of stock             $ 12,700 $ 4,500            
Unrealized gain (loss) on long term investments             3,900   $ (7,500) $ (1,200) $ 3,500      
Agenus | Accrued and other liabilities                            
License agreements                            
Accrued and other liabilities             $ 1,500     $ 1,500     $ 1,600  
Agenus | Minimum                            
License agreements                            
Share price (per share) | $ / shares             $ 4.28 $ 3.57   $ 4.28        
Agenus | Maximum                            
License agreements                            
Share price (per share) | $ / shares             $ 5.25 $ 4.21   $ 5.25        
Agenus | Stock purchase agreement                            
License agreements                            
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares   10.0                        
Purchase price of common stock   $ 60,000                        
Per share price | $ / shares $ 4.40 $ 6.00                        
Discount for lack of marketability $ 4,500                          
Fair value of shares on the issuance date 39,500                          
Total consideration paid $ 60,000                          
Long term investments     $ 39,500                 39,500    
Research and development expense                       $ 20,500